纳武利尤单抗联合克唑替尼一线治疗ALK阳性晚期NSCLC的1/2期研究
CheckMate 370 E组为单臂队列,评估纳武利尤单抗(240 mg每2周)联合克唑替尼(250 mg每日两次)一线治疗ALK易位阳性晚期NSCLC的安全性。前13例中5例(38%)发生严重肝毒性并停药,其中2例死亡,研究因≥3级肝毒性提前终止,结论不支持进一步评估该联合方案。
要点
- 前13例中5例(38%)出现严重肝毒性并停药,其中2例死亡。
- 5例(38%)达到部分缓解。
- 因≥3级肝毒性,入组关闭且联合治疗终止。
核心结论
- 研究结果不支持进一步评估纳武利尤单抗240 mg每2周联合克唑替尼250 mg每日两次方案。
研究设计与样本
- CheckMate 370 E组为单臂队列,评估一线纳武利尤单抗联合克唑替尼在ALK易位阳性晚期NSCLC患者中的安全性。
- 主要终点为安全性,若第17周时因治疗相关不良事件停药的患者比例≤20%则达到主要终点。
- 客观缓解率为次要终点,数据截止日期为2017年5月26日。
主要发现
- 前13例接受纳武利尤单抗联合克唑替尼的患者中,5例(38%)发生严重肝毒性并导致联合治疗停药。
- 严重肝毒性患者中2例死亡,严重肝毒性可能促成死亡。
- 5例(38%)达到部分缓解。
关键数值与推荐
- 安全性主要终点阈值:第17周因治疗相关不良事件停药比例≤20%。
- 实际前13例中38%因严重肝毒性停药,超过预设阈值。
- 因观察到≥3级肝毒性,入组关闭且联合治疗终止。
临床怎么用
- 不建议在ALK易位阳性晚期NSCLC一线治疗中联合使用纳武利尤单抗与克唑替尼。
- 临床应警惕该联合方案相关的严重肝毒性风险。
局限性
- 研究为单臂设计,样本量小(前13例)。
- 因安全性问题提前终止,未能进一步评估疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Crizotinib, an anaplastic lymphoma kinase (ALK) inhibitor, is a first-line treatment for ALK translocation-positive advanced non-small cell lung cancer (NSCLC); however, patients eventually progress. Immunotherapies, including the programmed death-1 inhibitor nivolumab, have resulted in durable responses and long-term overall survival in patients with NSCLC. We hypothesized that combining targeted therapy with immunotherapy could result in more patients with responses and/or more durable responses. Herein we report data from a study assessing nivolumab plus crizotinib in patients with previously untreated advanced ALK translocation-positive NSCLC. METHODS: Group E in CheckMate 370 was a single-arm cohort designed to evaluate the safety of first-line nivolumab (240 mg every 2 weeks) plus crizotinib (250 mg twice daily) in patients with ALK translocation-positive NSCLC. The primary endpoint of safety would be met if ≤20% of patients discontinued treatment due to treatment-related adverse events by week 17. Objective response rate was a secondary endpoint. A planned safety review occurred in November 2016; the data cutoff was May 26, 2017. RESULTS: Of the first 13 patients treated with nivolumab plus crizotinib, 5 (38%) developed severe hepatic toxicities leading to the discontinuation of the combination. Of these, two patients died and the presence of severe hepatic toxicities may have contributed to death. Enrollment was closed and combination treatment discontinued due to observed grade ≥3 hepatic toxicities. Five patients (38%) had a partial response. CONCLUSIONS: These findings do not support further evaluation of nivolumab 240 mg every 2 weeks plus crizotinib 250 mg twice daily.
引用
- Spigel DR, Reynolds C, Waterhouse D, et al. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol. 2018. PMID: 29518553. doi:10.1016/j.jtho.2018.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。